In December 2014 the U.S. Judicial Panel on Multidistrict Litigation began consolidating the Xarelto lawsuits. The lawsuits were consolidated into the Eastern District of Louisiana. Since December, any complaint that has been filed about Xarelto have been sent to Louisiana for the proceedings. Since all of these cases will be in one court, the proceedings will be more efficient because there will be less conflicts and errors.
Both sides have been doing their best to continue pushing the litigation in the right direction. There are over 500 Xarelto cases. All the plaintiffs who are part of the lawsuit have claimed that Xarelto is unsafe becuase of the bleeding risks and no antidote being available. Plaintiffs have also claimed that the manufacturers of the anticoagulant did not provide enough warnings about the serious side effects of Xarelto, including internal bleeding, hemorrhages, and blood clots.
The first bellwether trial has been scheduled for August 1, 2016. Whenever pre-trial proceedings are placed into a litigation like Xarelto, the purpose is to have as much valuable resources as possible in order to present everything to the juries. Every side will then make a decision on how the juries will conduct themselves regarding the proofs and evidence.
As it has been noted, Xarelto was approved by the FDA in 2011. It was approved because it was supposed to reduce blood clots in the patients who were having knee surgery or hip surgery. It was then approved to lower the stroke risks in patients with non-valvular AF. However, it has now been linked to hundreds of unfortunate events that have led to hospitalization and deaths.
If you or a loved one suffered from severe bleeding after taking Xarelto, please contact the Levensten Law Firm at 215-545-5600 or on our home page, or at www.xareltoinjurylawyer.com to learn how to file a claim for compensation for your injuries.